Woong Biotech Preparing Clinical Trials for 'FDA Virus Treatment'

[Asia Economy Reporter Jang Hyowon] Woong Bio Tech Co., Ltd. announced on the 3rd that it has received recognition from the U.S. Food and Drug Administration (FDA) for the excellent results of the virus eradication candidate substance Now-St and is embarking on a full-scale effort to launch new antimicrobial and antiviral drugs.

Now-St is a substance developed by Woong Bio Tech using proprietary core technology, and in March, it obtained test certification from the FDA for disinfection and sterilization that kills strains and viruses. During the certification process of Now-St, Escherichia coli, Staphylococcus, Salmonella, and Pseudomonas aeruginosa were eradicated by 99.9%. The company also stated that the device manufacturing Now-St was certified to eradicate SARS by 95.6%.

Additionally, based on clinical results showing that the substance is harmless to the human body, preparations for Phase 2 clinical trials are underway. A Woong Bio Tech official explained, “It is not only the first case in Korea but also a rare example worldwide that a disinfection and sterilization product that kills strains and viruses has been certified as harmless to the human body.”

He added, “It is highly significant that the FDA recognized the research achievement of finely adjusting the concentration of the Now-St substance, which has proven effective in eradicating COVID-19, and dissolving it in water,” and stated, “We hope that through the development of new antimicrobial and antiviral drugs using Now-St, Korea will be able to take a proactive approach to the prevention and eradication of the COVID-19 virus.”

This content was produced with the assistance of AI translation services.